Ethicon Launches ETHIZIA™ Hemostatic Patch, Clinically Proven to Halt Disruptive Bleeding

Image Source : Public Domain

Ethicon*, a Johnson & Johnson MedTech company,  announced the approval of ETHIZIA™, an adjunctive hemostat solution which has been clinically proven to achieve sustained hemostasis in difficult to control bleeding situations.¹ Comprised of unique synthetic polymer technology, ETHIZIA™ Hemostatic Sealing Patch is the first and only hemostatic matrix designed to be equally active and efficacious on both sides***.² Designed for maximum adaptability, it can be stuffed, rolled, pulled apart, trimmed and tailored,^3, 4 making it easy to handle in both open and minimally invasive surgeries.⁵ In 80% of clinical trial patients studied****, ETHIZIA™ Hemostatic Sealing Patch stopped bleeding in 30 seconds, an average of six times faster than the leading Fibrin Sealant Patch*****.^{6 7}

ETHIZIA™ Hemostatic Sealing Patch has received CE Mark approval as an adjunctive hemostat for disruptive bleeding on internal organs, except cardiovascular and neurological, and is expected to launch in EMEA in Q1 2024, and other key markets in North America, APAC and LATAM following regulatory approvals. 

"As a global leader in surgery, we are committed to empowering healthcare providers to safeguard patients from surgical complications by continuously delivering breakthrough solutions," said Vladimir Makatsaria, Company Group Chairman, Ethicon. "Disruptive bleeding can contribute to serious complications, and with the addition of ETHIZIA™ to our portfolio, we are well positioned to deliver critical hemostasis solutions for patients."

In May 2022, Ethicon acquired GATT Technologies B.V., a Netherlands-based company using differentiated synthetic polymer to create hemostatic and sealant products to address complex surgical bleeding and leak challenges. The acquisition of GATT and the addition of its synthetic technology complements Ethicon's current capabilities, enabling the development of innovative solutions that address critical unmet needs, such as ETHIZIA™ Hemostatic Sealing Patch which can offer sustained hemostasis in difficult to control bleeding situations.

As a global leader in surgery, Ethicon harnesses deep expertise to design surgical solutions that are smarter, less invasive, and more personalized. The introduction of ETHIZIA™ provides a unique design that surgeons can trust to work equally effective on both sides*** ⁸, giving surgeons the confidence they need in any surgical situation.